Neovacs S.A.

Neovacs obtains FDA ‘Fast Track’ designation for IFNα Kinoid in Lupus (SLE)

Neovacs signs production partnership with 3P Biopharmaceuticals, a leading GMP producer of biological drugs

NEOVACS ACQUIRES INTERFERON ALPHA MANUFACTURING TECHNOLOGY FROM AMEGABIOTECH

Neovacs enrolls the first U.S. Patient in Phase IIb study of IFNa Kinoid for treatment of Systemic Lupus Erythematosus (SLE)

Neovacs to attend Jefferies 2016 London Healthcare Conference November 16 & 17, 2016

Neovacs S.A. signs a cooperation agreement with the Department Immunology of Diabetes at the reputed Hospital Cochin in Paris